Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1228 ARTÍCULOS , VIENDO DEL 676 AL 690

[Mechanisms of Alzheimer's disease : Neuronal hyperactivity and hypoactivity as new therapeutic targets]

Busche MA, Staufenbiel M, Willem M, Haass C, Förstl H.

Nervenarzt. 2016 Nov;87(11):1163-1174. doi: 10.1007/s00115-015-0041-5.

Memantine Exacerbates Corrected QT Interval Prolongation in Alzheimer's Disease: A Case Report from an Unintentional Rechallenge

Kajitani K, Yanagimoto K, Monji A, Maruyama T.

J Am Geriatr Soc. 2016 Jan;64(1):232-3. doi: 10.1111/jgs.13897.

Validating Alzheimer's disease micro RNAs using next-generation sequencing

Keller A, Backes C, Haas J, Leidinger P, Maetzler W, Deuschle C, Berg D, Ruschil C, Galata V, Ruprecht K, Stähler C, Würstle M, Sickert D, Gogol M, Meder B, Meese E.

Alzheimers Dement. 2016 May;12(5):565-76. doi: 10.1016/j.jalz.2015.12.012. Epub 2016 Jan 22.

An Overview of Genome-Wide Association Studies in Alzheimer's Disease

Shen L, Jia J.

Neurosci Bull. 2016 Apr;32(2):183-90. doi: 10.1007/s12264-016-0011-3. Epub 2016 Jan 25.

Emerging amyloid disease-modifying drugs for Alzheimer's disease

Galimberti D, Scarpini E.

Expert Opin Emerg Drugs. 2016;21(1):5-7. doi: 10.1517/14728214.2016.1146678. Epub 2016 Feb 15.

Nicotinic Acetylcholine Receptors in the Pathophysiology of Al zheimer's Disease: The Role of Protein-Protein Interactions in Current and Future Treatment

Thomsen MS, Andreasen JT, Arvaniti M, Kohlmeier KA.

Curr Pharm Des. 2016;22(14):2015-34. doi: 10.2174/1381612822666160127112357.

Cholesterol, 24-Hydroxycholesterol, and 27-Hydroxycholesterol as Surrogate Biomarkers in Cerebrospinal Fluid in Mild Cognitive Impairment and Alzheimer's Disease: A Meta-Analysis

Wang HL, Wang YY, Liu XG, Kuo SH, Liu N, Song QY, Wang MW.

J Alzheimers Dis. 2016;51(1):45-55. doi: 10.3233/JAD-150734.

Differential Impairment of Cognitive and Affective Mentalizing Abilities in Neurodegenerative Dementias: Evidence from Behavioral Variant of Frontotemporal Dementia, Alzheimer's Disease, and Mild Cognitive Impairment

Dodich A, Cerami C, Crespi C, Canessa N, Lettieri G, Iannaccone S, Marcone A, Cappa SF, Cacioppo JT.

J Alzheimers Dis. 2016;50(4):1011-22. doi: 10.3233/JAD-150605.

Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials

Kennedy RE, Cutter GR, Wang G, Schneider LS.

J Alzheimers Dis. 2016;50(4):1205-15. doi: 10.3233/JAD-150847.

Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study

Nagata T, Shinagawa S, Nakajima S, Plitman E, Mihashi Y, Hayashi S, Mimura M, Nakayama K.

J Alzheimers Dis. 2016;50(3):839-45. doi: 10.3233/JAD-150869.

Progressive Language Impairment in an English-Italian Bilingual Woman With Alzheimer Disease: An 18-Month Follow-up

D'Antonio F, Imbriano L, Campanelli A, de Lena C, Trebbastoni A.

Alzheimer Dis Assoc Disord. 2016 Oct-Dec;30(4):354-356. doi: 10.1097/WAD.0000000000000139.

Pharmacotherpy and Alzheimer's Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach

Daulatzai MA.

Curr Pharm Des. 2016;22(16):2411-30. doi: 10.2174/1381612822666160203142111.

Survival in Frontotemporal Dementia Phenotypes: A Meta-Analysis

Kansal K, Mareddy M, Sloane KL, Minc AA, Rabins PV, McGready JB, Onyike CU.

Dement Geriatr Cogn Disord. 2016;41(1-2):109-22. doi: 10.1159/000443205. Epub 2016 Feb 9.

Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease

Teipel SJ, Cavedo E, Grothe MJ, Lista S, Galluzzi S, Colliot O, Chupin M, Bakardjian H, Dormont D, Dubois B, Hampel H; Hippocampus Study Group.

Neuropharmacology. 2016 Sep;108:128-35. doi: 10.1016/j.neuropharm.2016.02.005. Epub 2016 Feb 10.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias